pyrroles has been researched along with Nervous System Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Abdolghaffari, AH; Arab, ZN; Dehpour, AR; Jafari, RM; Khayatan, D; Momtaz, S; Razavi, SM; Zare, K | 1 |
| Beijnen, JH; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Haanen, JB; Huitema, AD; Kloth, JS; Lankheet, NA; Lolkema, MP; Mathijssen, RH; Schellens, JH; Sleijfer, S; Steeghs, N; Voest, EE | 1 |
| Cardona-Gómez, GP; Garcia-Segura, LM; Gutierrez-Vargas, JA; Muñoz-Manco, JI | 1 |
| Ashida, K; Hibberd, M; Jenkins, H; Jenkins, R; Nishimura, A; Ogama, Y; Okamoto, H; Sakurai, Y; Warrington, S; Yoneyama, T | 1 |
| Hillyer, J; Kwon, BK; Lee, JH; Mann, CM; Stammers, AM; Tetzlaff, W | 1 |
| Anthony, DC; Boekelheide, K; Graham, DG; Maschmann, NA; Richards, RG; Shaw, BR; Wolfram, JW | 1 |
| DeCaprio, AP; Olajos, EJ; Weber, P | 1 |
| Csanády, GA; Dietz, W; Filser, JG; Kessler, W; Kreuzer, PE; Richter, M; Störmer, A | 1 |
| Lawson, K | 1 |
| Kim, PJ; Markesbery, WR; Montine, KS; Montine, TJ; Olson, SJ | 1 |
| Batoréu, MC; dos Santos, AP; Mateus, ML | 1 |
| Bonetta, L | 1 |
| Irvine, DG | 1 |
| Autilio-Gambetti, L; Gambetti, P; Sayre, LM | 1 |
3 review(s) available for pyrroles and Nervous System Diseases
| Article | Year |
|---|---|
Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders.
Topics: Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Lipoxygenase Inhibitors; Nervous System Diseases; Pyrroles | 2021 |
Potassium channel activation: a potential therapeutic approach?
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Benzopyrans; Bronchodilator Agents; Calcium; Cardiovascular Diseases; Cromakalim; Hair; Humans; Intraocular Pressure; Muscle, Skeletal; Nervous System Diseases; Parasympatholytics; Patch-Clamp Techniques; Potassium Channels; Pyrroles; Reproduction; Respiratory Tract Diseases; Synaptic Transmission; Urologic Diseases; Vasodilator Agents | 1996 |
Pathogenesis of experimental giant neurofilamentous axonopathies: a unified hypothesis based on chemical modification of neurofilaments.
Topics: Animals; Axonal Transport; Axons; Chickens; Cytoskeleton; Disease Models, Animal; Glyceraldehyde-3-Phosphate Dehydrogenases; Hexanones; Humans; In Vitro Techniques; Intermediate Filament Proteins; Intermediate Filaments; Mice; Nervous System Diseases; Neurofilament Proteins; Nitriles; Phosphorylation; Pyrroles; Rats | 1985 |
3 trial(s) available for pyrroles and Nervous System Diseases
| Article | Year |
|---|---|
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Male; Middle Aged; Neoplasms; Nervous System Diseases; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Salvage Therapy; Sunitinib | 2014 |
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Topics: Adult; Asian People; Dose-Response Relationship, Drug; Double-Blind Method; Gastric Acid; Gastrointestinal Agents; Half-Life; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nervous System Diseases; Potassium; Pyrroles; Sulfonamides; United Kingdom; White People; Young Adult | 2015 |
Comparative estimation of the neurotoxic risks of N-hexane and N-heptane in rats and humans based on the formation of the metabolites 2,5-hexanedione and 2,5-heptanedione.
Topics: Administration, Inhalation; Adult; Animals; Body Burden; Cross-Linking Reagents; Half-Life; Heptanes; Hexanes; Hexanones; Humans; Ketones; Male; Nervous System Diseases; Pyrroles; Rats; Rats, Wistar; Risk Assessment | 1996 |
8 other study(ies) available for pyrroles and Nervous System Diseases
| Article | Year |
|---|---|
GluN2B N-methyl-D-aspartic acid receptor subunit mediates atorvastatin-Induced neuroprotection after focal cerebral ischemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Embryo, Mammalian; Heptanoic Acids; Male; Maze Learning; Nerve Tissue Proteins; Nervous System Diseases; Piperidines; Platelet Aggregation Inhibitors; Pyrroles; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recovery of Function; Somatosensory Cortex; Time Factors | 2014 |
Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury.
Topics: Analysis of Variance; Animals; Atorvastatin; Benzenesulfonates; Dietary Sucrose; Disease Models, Animal; Drug Administration Routes; Ectodysplasins; Exploratory Behavior; Food, Formulated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Motor Activity; Nervous System Diseases; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley; Sacrococcygeal Region; Simvastatin; Spinal Cord Injuries | 2010 |
Studies of the molecular pathogenesis of hexane neuropathy. II. Evidence that pyrrole derivatization of lysyl residues leads to protein crosslinking.
Topics: Cross-Linking Reagents; Electrophoresis, Polyacrylamide Gel; Hexanes; Hexanones; Lysine; Nervous System Diseases; Pyrroles | 1982 |
Covalent binding of a neurotoxic n-hexane metabolite: conversion of primary amines to substituted pyrrole adducts by 2,5-hexanedione.
Topics: Amines; Amino Acids; Animals; Chemical Phenomena; Chemistry; Chickens; Chromogenic Compounds; Female; Hexanes; Hexanones; Ketones; Nervous System Diseases; Proteins; Pyrroles | 1982 |
4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease.
Topics: Adult; Aged; Aged, 80 and over; Aldehydes; Alzheimer Disease; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Brain; DNA Adducts; Female; Genotype; Homozygote; Humans; Male; Middle Aged; Nerve Degeneration; Nervous System Diseases; Pyrroles | 1997 |
Interaction of zinc on biomarker responses in rats exposed to 2,5-hexanedione by two routes of exposure.
Topics: Administration, Oral; Animals; Biomarkers; Dose-Response Relationship, Drug; Drug Interactions; Hexanones; Injections, Intraperitoneal; Male; Nervous System Diseases; Neurotoxins; Pyrroles; Rats; Rats, Wistar; Zinc Acetate | 2001 |
Potential neurological value of statins increases.
Topics: Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Costs and Cost Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Nervous System Diseases; Pyrroles; United States | 2002 |
Pyrroles in neuropsychiatric and porphyric disorders: confirmation of a metabolite structure by synthesis.
Topics: Chromatography, Gel; Humans; Mental Disorders; Nervous System Diseases; Porphyrias; Pyrroles | 1978 |